An observational study in Leukemia, sponsored by Alliance for Clinical Trials in Oncology. Active, not recruiting at 77 sites in United States. Per ClinicalTrials.gov, last updated 2023-08-31.
Sponsored by Alliance for Clinical Trials in Oncology · Observational
RATIONALE: Studying samples of tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at tissue and blood samples from patients with acute myeloid leukemia.
OBJECTIVES:
OUTLINE: This is a multicenter study.
Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, and CBL mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 529 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →Alliance for Clinical Trials in Oncology is the lead sponsor of 499 studies on the registry; 27 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with acute myeloid leukemia
DISEASE CHARACTERISTICS:
Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
Genetic: DNA analysis · Genetic: DNA methylation analysis · Genetic: gene expression analysis · Genetic: mutation analysis · Genetic: polymerase chain reaction · Genetic: reverse transcriptase-polymerase chain reaction · Other: high performance liquid chromatography · Other: laboratory biomarker analysis
Presence of molecular markers that fulfill eligibility criteria in diagnostic samples from AML patients considered for CALGB therapeutic protocols
Time frame: baseline
Frequency of specific single-gene markers over-expression and levels of promoter methylation of specific genes
Time frame: baseline
Predictive value of specific single-gene markers
Time frame: baseline
Microarray multi-gene and multi-miR expression signatures
Time frame: baseline
This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alliance for Clinical Trials in Oncology